Ranking Invest

Vera Therapeutics, Inc.

Segmento: Healthcare Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Indicadores Básicos

Valor de Mercado

$ 1.41 Bi

IVR

0.10

IVR2

-0.28

Índices de Previsibilidade

Faturamento

0.00

Lucro

0.23

Margem

0.00

Índices de Tendência

Faturamento

0.00

Lucro

-10.66

Margem

0.00

Índices de Endividamento

DIV/PAT

-0.00

DIV/L4T

0.00

Dívida Líquida

-$ 625.00 mil

Patrimônio Líquido

$ 535.00 Mi

L4T

-$ 175.46 Mi

MM4T

0.00%

Dívidas
Dividendos
Cotação: $22.07

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre